Miranda-Duarte A, Kraus-Weisman A, Granados J, Villa AR

Idioma: Ingles.
Referencias bibliográficas: 45
Paginas: 236-243
Archivo PDF: 101.90 Kb.

RESUMEN

Objetivo. Determinar la asociación entre los alelos HLA de clase II y la probabilidad de desarrollar cáncer en pacientes con enfermedades reumáticas autoinmunes. Material y métodos. Estudio de casos y controles pareado en el que los pacientes con enfermedad reumática autoinmune, que desarrollaron posteriormente un tumor maligno (sólido o linfoproliferativo), fueron comparados con controles pareados por la misma enfermedad reumática autoinmune, sin cáncer y con una duración similar de la enfermedad. Las enfermedades reumáticas incluyeron artritis reumatoide, lupus eritematoso sistémico, síndrome de Sjögren primario, dermatomiositispolimiositis y esclerosis sistémica. La tipificación de HLA-DR fue realizada por iniciadores secuencia específico después de la amplificación de ADN por PCR (PCR-SSP). El análisis estadístico se realizó mediante regresión logística no condicional. Resultados. Los HLA-DRBI*02 y DRBI*03 estuvieron asociados significativa-mente con la probabilidad de desarrollar cáncer (OR = 5.2 y 4.9, respectivamente) independiente de la historia familiar de artritis reumatoide, cáncer, faringoamigdalitis recurren-te, alopecia y actividad clínica de artritis reumatoide. Conclusiones. Los resultados sugieren una asociación entre los alelos HLA de clase II con la probabilidad de desarrollar una neoplasia maligna en pacientes que sufren de una enfermedad reumática autoinmune.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Villa AR, Kraus A, Jiménez-Corona A, Sandino S, Velázquez- González A, Granados J, et al. Malignant neoplasms in autoimmune rheumatic diseases. Examination of the risk of developing a malignancy among five different rheumatic diseases in one institution. J Clin Rheumatol 2000; 6: 176-83.

2. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a metaanalysis. Arch Intern Med 2005; 165: 2337-44.

3. Isomäki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphoma, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978; 31: 691-6.

4. Prior P, Symmons DPM, Hawkins CF. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 1984; 43: 128-31.

5. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94.

6. Myllykangas-Luosojärvi R, Aho K, Isomäki H. Mortality from cancer in patients with rheumatoid arthritis. Scand J Rheumatol 1995; 24: 76-8.

7. Petterson T, Pukkala E, Tepolo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 437-9.

8. Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1050-4.

9. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH. Non Hodgkin lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 761-8.

10. Ragnarsson O, Grondal G, Steinsson K. Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 2003; 12: 687-91.

11. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1481-90.

12. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, et al. Increased risk of lymphoma in Sicca syndrome. Ann Int Med 1978; 89: 888-92.

13. Valesini G, Priori R, Bavoillot D, Osborn J, Danieli MG, Del Papa N, et al. Differential risk of non-Hodgkin lymphoma in Italian patients with primary Sjögren’s syndrome. J Rheumatol 1997; 24: 2376-80.

14. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer inci dence and lymphoma predictors. Ann Rheum Dis 2006; 65: 796-803.

15. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. New Engl JM 1992; 326: 363-7.

16. Airio A, Pukkala E, Isomäki H. Elevated cancer incidence in patients with dermatomyositis. A population based study. J Rheumatol 1995; 22: 1300-3.

17. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 2002; 41: 729-34.

18. Peters-Golden M, Wise RA, Hochberg M, Stevens MB, Wigley FM. Incidence of lung cancer in systemic sclerosis. J Rheumatol 1985; 12: 1136-9.

19. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995; 76: 910-4.

20. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003; 62: 728-31.

21. Sakkas LI, Moore DF, Akritidis NC. Cancer in families with systemic sclerosis. Am J Med Sci 1995; 310: 223-5.

22. Dieude P, Cornelis F. Genetic basis of rheumatoid arthritis. Joint Bone Spine 2005; 72: 520-6.

23. Smerdel-Ramoya A, Finholt C, Lilleby V, Gilboe IM, Harbo HF, Maslinski S, et al. Systemic lupus erythematosus and the extended major histocompatibility complex- evidence for several predisposing loci. Rheumatology 2005; 44: 1368-73.

24. Kerttula TO, Collin P, Polvi A, Korpela M, Partanen J, Maki M. Distinct immunologic features of Finnish Sjogren’s syndrome patients with HLA alleles DRB1*0301, DQA1*0501, and DQB1*0201. Alterations in circulating T cell receptor gamma/ delta subsets. Arthritis Rheum 1996; 39: 1733-9.

25. Vavrincova P, Havelka, Cerna M, Stastny P. HLA class II alleles in juvenile dermatomyositis. J Rheumatol Suppl 1993; 37: 17-8.

26. Silva B, Vargas-Alarcón G, Zúñiga-Ramos J, Rodríguez-Reyna TS, Hernández-Martínez B, Osnaya N, et al. Genetic features of Mexican women predisposing to cancer of the uterine cervix. Hum Pathol 1999; 30: 626-8.

27. Golubovic G, Stajic M, Stolic I, Nikolic JA, Neskovic AN, Pandey L. Histocompatibility antigens in patients with hepatocellular carcinoma. Z Gastroenterol 1996; 34: 15-20.

28. Oza AM, Tonks S, Lim J, Fleetwood MA, Lister TA, Bodmer JG. A clinical and epidemiological study of human leukocyte antigen-DPB alleles in Hodgkin’s disease. Cancer Res 1994; 54: 5101-05.

29. Chiewsilp P, Sujirachato K, Mongkolsuk T, Junpong S, Jootar S, Hathirat P. Preliminary study of HLA-ABCDR antigens in CML, ANLL, thalassemia and severe aplastic anemia in Thais. J Med Assoc Thai Suppl 2000; 83: S130-S136.

30. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis. Arthritis Rheum 1988; 31: 315-24.

31. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.

32. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren’s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993; 36: 340-7.

33. Bohan A, Petter JB. Polymyositis and dermatomyositis (First of two parts). New Engl J Med 1975; 292: 344-7.

34. Subcommittee for the Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.

35. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in two hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantations. Tissue Antigens 1992; 39: 225-35.

36. Boon T, Cerottini JC, Van den Eynde B, Van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 337-65.

37. Chaudhuri S, Cariappa A, Tang M, Bell D, Haber DA, Isselbacher KJ, et al. Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. PNAS 2000: 97: 11451-4.

38. Gadducci A, Ferdeghini M, Castellani C, Annicchiarico C, Gagetti O, Prontera C, et al. Serum levels of tumour necrosis factor (TNF), soluble receptors for TNF (55 and 75 kDa sTNFr) and soluble CD14 (sCD14) in epithelial ovarian cancer. Gynecol Oncol 1995; 58: 184-8.

39. Fossum B, Breivik J, Meling GI, Gedde-Dahl T. 3rd, Hansen T, Knutsen I, et al. A K-ras 13 Gly-Asp mutation is recognized by HLA-DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancer harbouring this mutation? Int J Cancer 1994; 58: 506-11.

40. Naschitz JE, Rosner I, Rozenbaum M, Elias N, Yeshurun D. Cancer associated rheumatic disorders: clues to occult neoplasia. Semin Arthritis Rheum 1995; 24: 231-41.

41. András C, Csiki Z, Ponyi A, Illés A, Dankó K. Paraneoplastic rheumatic syndromes. Rheumatol Int 2006; 26: 376-82.

42. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994; 21: 1855-9.

43. Bradford Hill A. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.

44. Villa AR, Kraus A, Alarcon-Segovia D. Autoimmune rheumatic diseases and cancer: evidence of causality? In: Cancer and autoimmunity. Amsterdam, The Netherlands: Ed. Elsevier Science; 2000, p. 111–7.

45. Toloza SM, Roseman JM, Alarcón GS, McGwin G Jr, Uribe AG, Fessler BJ, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum 2004; 50: 3177-86.